Susann Winter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Susann Winter has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Uwe Platzbecker
Universitätsklinikum Carl Gustav Carus, Dresden, Germany
8 shared publications - Martin Bornhäuser
Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany
7 shared publications - Jan-Niklas Eckardt
Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany
5 shared publications - Jan Moritz Middeke
Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany
4 shared publications - Freya Schulze
Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany
3 shared publications Katja Sockel
Department of Medicine I, Medical Faculty and University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
3 shared publications
Latest Publications
- Open Access
Multimodal Artificial Intelligence Fusion Models to Predict Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia
Venetoclax and azacitidine (ven-aza) is a standard of care therapy for newly diagnosed acute myeloid leukemia (AML) patients unfit to receive intensive therapy, and may also be appropriate for certain fit patients. Models predicting response to ven-aza currently focus predominantly on genetics. Here, we present two multimodal fusion models: a custom ResNet-34-based model and a pathology foundation model fine-tuned for bone marrow smear (BMS) images that combine clinical and genetic variables with whole slide images. Training on 193 newly diagnosed AML patients who received ven-aza, we obtained an area-under-the-receiver-operating-characteristic (AUROC) of 0.79 and 0.82 for the ResNet-based and fine-tuned foundation models in a heldout test set, and 0.76 and 0.73 in an external validation set, predicting best response to this therapy. Sensitivity analysis showed that fusing image data with clinical and genetic variables outperformed training on either modality alone. In univariable and multivariable analyses, image-based classification was an independent predictive marker, second only in effect size to IDH1/2 mutation status, outperforming other genetic alterations. Image-based explainability showed high model attention on myeloblasts, suggesting previously unrecognized cell-specific patterns associated with response. Our findings suggest BMS images complement genetic biomarkers to refine outcome prediction in ven-aza treatment and incentivize AI-supported outcome prediction, including bone marrow morphology.
Open AccessMultimodal Artificial Intelligence Fusion Models to Predict Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia
Venetoclax and azacitidine (ven-aza) is a standard of care therapy for newly diagnosed acute myeloid leukemia (AML) patients unfit to receive intensive therapy, and may also be appropriate for certain fit patients. Models predicting response to ven-aza currently focus predominantly on genetics. Here, we present two multimodal fusion models: a custom ResNet-34-based model and a pathology foundation model fine-tuned for bone marrow smear (BMS) images that combine clinical and genetic variables with whole slide images. Training on 193 newly diagnosed AML patients who received ven-aza, we obtained an area-under-the-receiver-operating-characteristic (AUROC) of 0.79 and 0.82 for the ResNet-based and fine-tuned foundation models in a heldout test set, and 0.76 and 0.73 in an external validation set, predicting best response to this therapy. Sensitivity analysis showed that fusing image data with clinical and genetic variables outperformed training on either modality alone. In univariable and multivariable analyses, image-based classification was an independent predictive marker, second only in effect size to IDH1/2 mutation status, outperforming other genetic alterations. Image-based explainability showed high model attention on myeloblasts, suggesting previously unrecognized cell-specific patterns associated with response. Our findings suggest BMS images complement genetic biomarkers to refine outcome prediction in ven-aza treatment and incentivize AI-supported outcome prediction, including bone marrow morphology.
- Open Access
- 9 October 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (11) , 2573-2583
Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study
Myelodysplastic neoplasms (MDS) are characterized by insufficient hematopoiesis and alterations of the bone marrow microenvironment. However, bone health in MDS has not been evaluated in a prospective, longitudinal setting. Within the Bo ne and Hem atology in E lderly (BoHemE) study, bone mineral density (represented as T-score) and bone-specific serum markers were assessed in patients with MDS ( n = 111; 36% female) and age-matched controls ( n = 84; 55% female) at baseline and after 3 years. At baseline, patients with MDS had a lower T-score [−0.2; p < 0.05] compared to controls, which was mainly attributed to the lower T-score in women with MDS [−0.3; p < 0.05]. Furthermore, the DNMT3A mutation was associated with a lower T-score within the MDS cohort [−0.7; p < 0.05], but the occurrence in controls had no effect. Albumin-adjusted calcium and phosphate levels correlated with T-scores within the MDS cohort [ p < 0.0001 and p < 0.01, respectively], independent of age, sex, MDS duration, IPSS-M score, or transfusion dependence. Quality of life was lower in patients with MDS [ p < 0.01], and remained stable over 3 years, whereas T-scores declined [−0.3; p < 0.05]. The presence of osteoporosis was associated with poor overall survival in MDS [ p < 0.01]. In conclusion, bone health should be evaluated as part of the diagnostic work-up and clinical management of MDS.
- 9 October 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (11) , 2573-2583
Open AccessBone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study
Myelodysplastic neoplasms (MDS) are characterized by insufficient hematopoiesis and alterations of the bone marrow microenvironment. However, bone health in MDS has not been evaluated in a prospective, longitudinal setting. Within the Bo ne and Hem atology in E lderly (BoHemE) study, bone mineral density (represented as T-score) and bone-specific serum markers were assessed in patients with MDS ( n = 111; 36% female) and age-matched controls ( n = 84; 55% female) at baseline and after 3 years. At baseline, patients with MDS had a lower T-score [−0.2; p < 0.05] compared to controls, which was mainly attributed to the lower T-score in women with MDS [−0.3; p < 0.05]. Furthermore, the DNMT3A mutation was associated with a lower T-score within the MDS cohort [−0.7; p < 0.05], but the occurrence in controls had no effect. Albumin-adjusted calcium and phosphate levels correlated with T-scores within the MDS cohort [ p < 0.0001 and p < 0.01, respectively], independent of age, sex, MDS duration, IPSS-M score, or transfusion dependence. Quality of life was lower in patients with MDS [ p < 0.01], and remained stable over 3 years, whereas T-scores declined [−0.3; p < 0.05]. The presence of osteoporosis was associated with poor overall survival in MDS [ p < 0.01]. In conclusion, bone health should be evaluated as part of the diagnostic work-up and clinical management of MDS.
- Open Access
Benchmarking ten frontier large language models on 1,477 board style multiple choice questions in hematology
Large Language Models (LLMs) are increasingly used by clinicians and patients for medical queries, yet their accuracy and safety at the specialist level in hematology remain insufficiently characterised. We benchmarked ten frontier proprietary and open-weight LLMs across two generations on 1,477 board-style hematology multiple-choice questions (MCQs) derived from five educational datasets spanning nine disease areas and six clinical skill domains, including text-only and multimodal case vignettes. Claude Opus 5 had the highest mean accuracy (92.7% text, 76.9% multimodal), followed closely by Gemini-3.1 Pro (91.4% and 78.7%), Gemini-3.6 Flash (91.0% and 74.8%) and GPT-5.6 Sol (89.9% and 76.7%). Accuracy significantly correlated with model size both for text-only and multimodal MCQs. Between model generations, the largest improvements in accuracy were seen for open-weight models whereas proprietary models showed only marginal gains. In error analysis, top-performing models exhibited highly concordant failure patterns, suggesting shared limitations on challenging cases. Frontier LLMs exhibit substantial specialist hematology knowledge across diverse subspecialist domains and clinical skill sets. Yet, despite high accuracy on board-style questions in hematology, continuous expert-on-the-loop output monitoring is paramount.
Open AccessBenchmarking ten frontier large language models on 1,477 board style multiple choice questions in hematology
Large Language Models (LLMs) are increasingly used by clinicians and patients for medical queries, yet their accuracy and safety at the specialist level in hematology remain insufficiently characterised. We benchmarked ten frontier proprietary and open-weight LLMs across two generations on 1,477 board-style hematology multiple-choice questions (MCQs) derived from five educational datasets spanning nine disease areas and six clinical skill domains, including text-only and multimodal case vignettes. Claude Opus 5 had the highest mean accuracy (92.7% text, 76.9% multimodal), followed closely by Gemini-3.1 Pro (91.4% and 78.7%), Gemini-3.6 Flash (91.0% and 74.8%) and GPT-5.6 Sol (89.9% and 76.7%). Accuracy significantly correlated with model size both for text-only and multimodal MCQs. Between model generations, the largest improvements in accuracy were seen for open-weight models whereas proprietary models showed only marginal gains. In error analysis, top-performing models exhibited highly concordant failure patterns, suggesting shared limitations on challenging cases. Frontier LLMs exhibit substantial specialist hematology knowledge across diverse subspecialist domains and clinical skill sets. Yet, despite high accuracy on board-style questions in hematology, continuous expert-on-the-loop output monitoring is paramount.
- Open Access
Vision Language Models Fail to Reliably Detect Acute Myeloid Leukemia in Bone Marrow Smears
Hematologic diagnostics and especially cytomorphologic assessment are time-intensive and require high levels of expertise. Vision Language Models (VLM) show promise in medical image analysis in radiology and histopathology, while an evaluation on detecting acute myeloid leukemia (AML) is lacking. Our goal was to evaluate three Vision Language Models regarding their diagnostic accuracy and safety in clinical decision support in detecting AML from digitized bone marrow smears (BMS). Whole slide images were obtained from bone marrow smears of 50 AML patients and 50 bone marrow donors. Ten representative fields of view per sample were extracted manually. Three VLMs were used, two of which are considered generalist models (Qwen3.5-397B-A17B-FP8, GLM-4.6V-FP8), while the other one is a medically adapted model (Medgemma-27b-it). All models performed zero-shot analysis using two prompting strategies: First, a context-rich prompt requesting reporting of WHO/FAB diagnostic criteria in a structured manner, and secondly a minimal prompt without specific hematologic context. Overall diagnostic accuracy was poor for all models as they exhibited the overwhelming tendency to classify most samples as leukemic: With context-rich prompts, GLM4.6 identified 90% of leukemic samples while also labeling 92% of bone marrow donors as AML. The medical specialist model MedGemma-27b showed similar failure, misclassifying 86% of healthy donors and correctly detecting AML in only 66% of cases. Qwen3.5 performed best under detailed prompting, achieving a specificity of 0.26 and accuracy of 0.51. Accuracy of all models improved with context-free prompts (accuracies range 0.47-0.79), yet they still lacked the ability to correctly distinguish between leukemia and healthy bone marrow. Qwen3.5 was the only model to maintain meaningful specificity (0.64) and correctly identified 94% of AML, yielding an overall accuracy of 0.79. Morphologic feature-level agreement with human expert reports was poor across all models, indicating poor recognition of cell-level morphologies. This failure is likely driven by the fact that pathology imaging archives are vastly scraped during model training while hematological samples are not as widely available and therefore, hematology is an out-of-bounds use-case for these models, rendering them currently unsuitable for clinical decision support in hematology.
Open AccessVision Language Models Fail to Reliably Detect Acute Myeloid Leukemia in Bone Marrow Smears
Hematologic diagnostics and especially cytomorphologic assessment are time-intensive and require high levels of expertise. Vision Language Models (VLM) show promise in medical image analysis in radiology and histopathology, while an evaluation on detecting acute myeloid leukemia (AML) is lacking. Our goal was to evaluate three Vision Language Models regarding their diagnostic accuracy and safety in clinical decision support in detecting AML from digitized bone marrow smears (BMS). Whole slide images were obtained from bone marrow smears of 50 AML patients and 50 bone marrow donors. Ten representative fields of view per sample were extracted manually. Three VLMs were used, two of which are considered generalist models (Qwen3.5-397B-A17B-FP8, GLM-4.6V-FP8), while the other one is a medically adapted model (Medgemma-27b-it). All models performed zero-shot analysis using two prompting strategies: First, a context-rich prompt requesting reporting of WHO/FAB diagnostic criteria in a structured manner, and secondly a minimal prompt without specific hematologic context. Overall diagnostic accuracy was poor for all models as they exhibited the overwhelming tendency to classify most samples as leukemic: With context-rich prompts, GLM4.6 identified 90% of leukemic samples while also labeling 92% of bone marrow donors as AML. The medical specialist model MedGemma-27b showed similar failure, misclassifying 86% of healthy donors and correctly detecting AML in only 66% of cases. Qwen3.5 performed best under detailed prompting, achieving a specificity of 0.26 and accuracy of 0.51. Accuracy of all models improved with context-free prompts (accuracies range 0.47-0.79), yet they still lacked the ability to correctly distinguish between leukemia and healthy bone marrow. Qwen3.5 was the only model to maintain meaningful specificity (0.64) and correctly identified 94% of AML, yielding an overall accuracy of 0.79. Morphologic feature-level agreement with human expert reports was poor across all models, indicating poor recognition of cell-level morphologies. This failure is likely driven by the fact that pathology imaging archives are vastly scraped during model training while hematological samples are not as widely available and therefore, hematology is an out-of-bounds use-case for these models, rendering them currently unsuitable for clinical decision support in hematology.
- Open Access
In Silico Trial Simulation with Artificial Intelligence-Generated Synthetic Control Cohorts Reproduces Results of a Randomized Controlled Trial in Acute Myeloid Leukemia
Rising costs, slow accrual and molecular sub-stratification of cancers necessitate novel clinical trial designs. We demonstrate that artificial intelligence-generated synthetic patients can replace real controls to reproduce results of the SORAML trial. Using external multimodal data from 1,377 acute myeloid leukemia (AML) patients from previous trials and a real-world registry, we fine-tuned a tabular foundation model to generate synthetic patients, reproducing clinical and genetic features and outcome associations. Synthetic patients were then matched to the original SORAML intervention group using Cox risk scores, replacing the original control and reproducing the original trial result with near-identical median event-free survival (EFS) and treatment effect (original hazard ratio [HR] 0.64, 95%-confidence interval [CI] 0.47–0.87, p =0.004; with synthetic control HR 0.66, 95%-CI 0.48– 0.90, p =0.009). Our findings demonstrate that AI-generated synthetic patients can serve as statistically rigorous controls supporting novel trial designs.
Open AccessIn Silico Trial Simulation with Artificial Intelligence-Generated Synthetic Control Cohorts Reproduces Results of a Randomized Controlled Trial in Acute Myeloid Leukemia
Rising costs, slow accrual and molecular sub-stratification of cancers necessitate novel clinical trial designs. We demonstrate that artificial intelligence-generated synthetic patients can replace real controls to reproduce results of the SORAML trial. Using external multimodal data from 1,377 acute myeloid leukemia (AML) patients from previous trials and a real-world registry, we fine-tuned a tabular foundation model to generate synthetic patients, reproducing clinical and genetic features and outcome associations. Synthetic patients were then matched to the original SORAML intervention group using Cox risk scores, replacing the original control and reproducing the original trial result with near-identical median event-free survival (EFS) and treatment effect (original hazard ratio [HR] 0.64, 95%-confidence interval [CI] 0.47–0.87, p =0.004; with synthetic control HR 0.66, 95%-CI 0.48– 0.90, p =0.009). Our findings demonstrate that AI-generated synthetic patients can serve as statistically rigorous controls supporting novel trial designs.
- Top Cited PapersOpen Access
- 18 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10042
Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia
Somatic mutations in hematopoietic stem/progenitor cells (HSPCs) can lead to clonal hematopoiesis of indeterminate potential (CHIP) and progression to myelodysplastic syndromes (MDS). Using single-cell and anatomical profiling of a large cohort of human bone marrow (BM), we show that the HSPC BM niche in CHIP and MDS is undergoing inflammatory remodeling. This includes loss of CXCL12⁺ adipogenic stromal cells and the emergence of a distinct population of inflammatory mesenchymal stromal cells (iMSCs), which arise in CHIP and become more prevalent in MDS. Functional studies in primary BM HSPC-MSC co-cultures reveals that healthy aged and CHIP HSPCs activate stromal support, while MDS HSPCs fail to do so. In contrast, MDS blasts further suppress HSPC support and trigger inflammation, indicating disease-stage-specific stromal disruption. In parallel, we show that iMSCs retain partial support and angiogenic potential in MDS, coinciding with expanded BM vasculature. Additionally, we identify IFN-responsive T cells that preferentially interact with iMSCs, potentially reinforcing local inflammation. These findings position iMSCs as central mediators of early BM niche dysfunction and potential therapeutic targets for intercepting pre-malignant hematopoiesis.
- 18 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10042
Top Cited PapersOpen AccessInflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia
Somatic mutations in hematopoietic stem/progenitor cells (HSPCs) can lead to clonal hematopoiesis of indeterminate potential (CHIP) and progression to myelodysplastic syndromes (MDS). Using single-cell and anatomical profiling of a large cohort of human bone marrow (BM), we show that the HSPC BM niche in CHIP and MDS is undergoing inflammatory remodeling. This includes loss of CXCL12⁺ adipogenic stromal cells and the emergence of a distinct population of inflammatory mesenchymal stromal cells (iMSCs), which arise in CHIP and become more prevalent in MDS. Functional studies in primary BM HSPC-MSC co-cultures reveals that healthy aged and CHIP HSPCs activate stromal support, while MDS HSPCs fail to do so. In contrast, MDS blasts further suppress HSPC support and trigger inflammation, indicating disease-stage-specific stromal disruption. In parallel, we show that iMSCs retain partial support and angiogenic potential in MDS, coinciding with expanded BM vasculature. Additionally, we identify IFN-responsive T cells that preferentially interact with iMSCs, potentially reinforcing local inflammation. These findings position iMSCs as central mediators of early BM niche dysfunction and potential therapeutic targets for intercepting pre-malignant hematopoiesis.
- Top Cited PapersOpen Access
- 7 May 2025
- Published by Wiley in HemaSphere
- Vol. 9 (5) , e70132
Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
Risk stratification in acute myeloid leukemia (AML) is driven by genetics, yet patient age substantially influences therapeutic decisions. To evaluate how age alters the prognostic impact of genetic mutations, we pooled data from 3062 pediatric and adult AML patients from multiple cohorts. Signaling pathway mutations dominated in younger patients, while mutations in epigenetic regulators, spliceosome genes, and TP53 alterations became more frequent with increasing age. Machine learning models were trained to identify prognostic variables and predict complete remission and 2‐year overall survival, achieving area‐under‐the‐curve scores of 0.801 and 0.791, respectively. Using Shapley (SHAP) values, we quantified the contribution of each variable to model decisions and traced their impact across six age groups: infants, children, adolescents/young adults, adults, seniors, and elderly. The highest contributions to model decisions among genetic variables were found for alterations of NPM1 , CEBPA , inv(16), and t(8;21) conferring favorable risk and alterations of TP53, RUNX1, ASXL1 , del(5q), ‐7, and ‐17 conferring adverse risk, while FLT3 ‐ITD had an ambiguous role conferring favorable treatment responses yet poor overall survival. Age significantly modified the prognostic value of genetic alterations, with no single alteration consistently predicting outcomes across all age groups. Specific alterations associated with aging such as TP53 , ASXL1 , or del(5q) posed a disproportionately higher risk in younger patients. These results challenge uniform risk stratification models and highlight the need for context‐sensitive AML treatment strategies.
- 7 May 2025
- Published by Wiley in HemaSphere
- Vol. 9 (5) , e70132
Top Cited PapersOpen AccessAge‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
Risk stratification in acute myeloid leukemia (AML) is driven by genetics, yet patient age substantially influences therapeutic decisions. To evaluate how age alters the prognostic impact of genetic mutations, we pooled data from 3062 pediatric and adult AML patients from multiple cohorts. Signaling pathway mutations dominated in younger patients, while mutations in epigenetic regulators, spliceosome genes, and TP53 alterations became more frequent with increasing age. Machine learning models were trained to identify prognostic variables and predict complete remission and 2‐year overall survival, achieving area‐under‐the‐curve scores of 0.801 and 0.791, respectively. Using Shapley (SHAP) values, we quantified the contribution of each variable to model decisions and traced their impact across six age groups: infants, children, adolescents/young adults, adults, seniors, and elderly. The highest contributions to model decisions among genetic variables were found for alterations of NPM1 , CEBPA , inv(16), and t(8;21) conferring favorable risk and alterations of TP53, RUNX1, ASXL1 , del(5q), ‐7, and ‐17 conferring adverse risk, while FLT3 ‐ITD had an ambiguous role conferring favorable treatment responses yet poor overall survival. Age significantly modified the prognostic value of genetic alterations, with no single alteration consistently predicting outcomes across all age groups. Specific alterations associated with aging such as TP53 , ASXL1 , or del(5q) posed a disproportionately higher risk in younger patients. These results challenge uniform risk stratification models and highlight the need for context‐sensitive AML treatment strategies.
- Open Access
Inflammatory Mesenchymal Stromal Cells and IFN-responsive T cells are key mediators of human bone marrow niche remodeling in CHIP and MDS
Somatic mutations in hematopoietic stem/progenitor cells (HSPCs) can lead to clonal hematopoiesis of indeterminate potential (CHIP), potentially progressing to myelodysplastic syndromes (MDS). Here, we investigated how CHIP and MDS remodel the human bone marrow (BM) niche relative to healthy elderly donors, using single cell and anatomical analyses in a large BM cohort. We found distinct inflammatory remodeling of the BM in CHIP and MDS. Furthermore, the stromal compartment progressively lost its HSPC-supportive adipogenic CXCL12-abundant reticular cells while an inflammatory mesenchymal stroma cell (iMSCs) population emerged in CHIP, which expanded in MDS. iMSCs exhibited distinct functional signatures in CHIP and MDS, retaining residual HSPC-support and angiogenic activity in MDS, corresponding with an increase in microvasculature in the MDS niche. Additionally, an IFN-responsive T cell population was linked to fueling inflammation in the stroma. Overall, these findings open new avenues for early intervention in hematological malignancies.
Open AccessInflammatory Mesenchymal Stromal Cells and IFN-responsive T cells are key mediators of human bone marrow niche remodeling in CHIP and MDS
Somatic mutations in hematopoietic stem/progenitor cells (HSPCs) can lead to clonal hematopoiesis of indeterminate potential (CHIP), potentially progressing to myelodysplastic syndromes (MDS). Here, we investigated how CHIP and MDS remodel the human bone marrow (BM) niche relative to healthy elderly donors, using single cell and anatomical analyses in a large BM cohort. We found distinct inflammatory remodeling of the BM in CHIP and MDS. Furthermore, the stromal compartment progressively lost its HSPC-supportive adipogenic CXCL12-abundant reticular cells while an inflammatory mesenchymal stroma cell (iMSCs) population emerged in CHIP, which expanded in MDS. iMSCs exhibited distinct functional signatures in CHIP and MDS, retaining residual HSPC-support and angiogenic activity in MDS, corresponding with an increase in microvasculature in the MDS niche. Additionally, an IFN-responsive T cell population was linked to fueling inflammation in the stroma. Overall, these findings open new avenues for early intervention in hematological malignancies.
- Open Access
- 3 October 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (14) , 1532-1542
Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
Improved long-term survival rates after allogeneic hematopoietic cell transplantation (alloHCT) make family planning for young adult cancer survivors an important topic. However, treatment-related infertility risk poses challenges. To assess pregnancy and birth rates in a contemporary cohort, we conducted a national multicenter study using data from the German Transplant Registry, focusing on adult women aged 18 to 40 years who underwent alloHCT between 2003 and 2018. Of 2654 women who underwent transplantation, 50 women experienced 74 pregnancies, occurring at a median of 4.7 years after transplant. Fifty-seven of these resulted in live births (77%). The annual first birth rate among HCT recipients was 0.45%, which is >6 times lower than in the general population. The probability of a live birth 10 years after HCT was 3.4%. Factors associated with an increased likelihood of pregnancy were younger age at alloHCT, nonmalignant transplant indications, no total body irradiation or a cumulative dose of <8 Gy, and nonmyeloablative/reduced-intensity conditioning. Notably, 72% of pregnancies occurred spontaneously, with assisted reproductive technologies used in the remaining cases. Preterm delivery and low birth weight were more common than in the general population. This study represents the largest data set reporting pregnancies in a cohort of adult female alloHCT recipients. Our findings underscore a meaningful chance of pregnancy in alloHCT recipients. Assisted reproductive technologies techniques are important and funding should be made available. However, the potential for spontaneous pregnancies should not be underestimated, and patients should be informed of the possibility of unexpected pregnancy despite reduced fertility. Further research is warranted to understand the impact of conditioning decisions on fertility preservation.
- 3 October 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (14) , 1532-1542
Open AccessHope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
Improved long-term survival rates after allogeneic hematopoietic cell transplantation (alloHCT) make family planning for young adult cancer survivors an important topic. However, treatment-related infertility risk poses challenges. To assess pregnancy and birth rates in a contemporary cohort, we conducted a national multicenter study using data from the German Transplant Registry, focusing on adult women aged 18 to 40 years who underwent alloHCT between 2003 and 2018. Of 2654 women who underwent transplantation, 50 women experienced 74 pregnancies, occurring at a median of 4.7 years after transplant. Fifty-seven of these resulted in live births (77%). The annual first birth rate among HCT recipients was 0.45%, which is >6 times lower than in the general population. The probability of a live birth 10 years after HCT was 3.4%. Factors associated with an increased likelihood of pregnancy were younger age at alloHCT, nonmalignant transplant indications, no total body irradiation or a cumulative dose of <8 Gy, and nonmyeloablative/reduced-intensity conditioning. Notably, 72% of pregnancies occurred spontaneously, with assisted reproductive technologies used in the remaining cases. Preterm delivery and low birth weight were more common than in the general population. This study represents the largest data set reporting pregnancies in a cohort of adult female alloHCT recipients. Our findings underscore a meaningful chance of pregnancy in alloHCT recipients. Assisted reproductive technologies techniques are important and funding should be made available. However, the potential for spontaneous pregnancies should not be underestimated, and patients should be informed of the possibility of unexpected pregnancy despite reduced fertility. Further research is warranted to understand the impact of conditioning decisions on fertility preservation.
- Open Access
- 17 April 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (6) , 1427-1431
Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms
- 17 April 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (6) , 1427-1431
Open AccessMutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms